First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung CancerLeora Horn, Stephen V. Liu, Aaron S. Mansfield et al.|New England Journal of Medicine|2018Cited by 3.5k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung CancerAlexander Drilon, Vivek Subbiah, Benjamin Besse et al.|New England Journal of Medicine|2020Cited by 835
HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (HER3-DXd) in Epidermal Growth Factor Receptor–Mutated Non–Small-Cell Lung Cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based ChemotherapyHelena A. Yu, Pasi A. Jänne, Yasushi Goto et al.|Journal of Clinical Oncology|2023Cited by 224
CAR-macrophage therapy for HER2-overexpressing advanced solid tumors: a phase 1 trialKim A. Reiss, Yara Abdou, Mathew G. Angelos et al.|Nature Medicine|2025Cited by 189
First-in-Human, Phase I Dose-Escalation and Dose-Expansion Study of Trophoblast Cell-Surface Antigen 2–Directed Antibody-Drug Conjugate Datopotamab Deruxtecan in Non–Small-Cell Lung Cancer: TROPION-PanTumor01Toshio Shimizu, Rebecca S. Heist, Jacob Sands et al.|Journal of Clinical Oncology|2023Cited by 168